Search Results

FACT-Cog Functional Assessment of Cancer Therapy - Cognitive Function For patients with Cognitive function issues LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Cog measure: MEASURE NAME: Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) VERSION: 3 NUMBER OF ITEMS: 37 PATIENT POPULATION: Cancer patients 18 years and older with chemotherapy-induced cognitive problems RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Perceived Cognitive Impairments, Impact of Perceived Cognitive Impairments on QoL, Comments from Others, Perceived Cognitive Abilities TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and primary scores possible. RELATED MEASURES: FACIT-Fatigue , FACT-G , FACT-ES DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Cog can be obtained by registering for permission. Users are not permitted to translate the FACT-Cog without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Cog may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cheung, Y., Shwe, M., Chui, W., Chay, W., Ang, S., Dent, R., Yap, Y., Lo, S., Ng, R., & Chan, A. Effects of Chemotherapy and Psychosocial Distress on Perceived Cognitive Disturbances in Asian Breast Cancer Patients. The Annals of Pharmacotherapy 2012; 46: 1645-1655. doi: 10.1345/aph.1R408. Hajj A, Salameh P, Khoury R, Hachem R, Sacre H, Chahine G, Kattan J, Rabbaa Khabbaz L. Psychometric properties of the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale. Future Oncol. 2022 Oct;18(33):3741-3753. doi: 10.2217/fon-2022-0438. Epub 2022 Nov 8. PMID: 36345984. Hajj A, Khoury R, Hachem R, Awad A, Hallit S, Sacre H, Nasr F, Karak FE, Chahine G, Kattan J, Khabbaz LR. Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the "CAGE-Cog" study. BMC Cancer. 2022 Sep 19;22(1):996. doi: 10.1186/s12885-022-10077-6. PMID: 36123640; PMCID: PMC9487123. Jacobs, S., Jacobsen, P., Booth-Jones, am., Wagner, L., & Anasetti, C. Evaluation of the Functional Assessment of Cancer Therapy Cognitive Scale with Hematopoetic Stem Cell Transplant Patients. Journal of Pain and Symptom Management 2007; 33(1): 13-23. doi: 10.1016/j.jpainsymman.2006.06.011. Joly, F., Lange, M., Rigal, O., Correia, H., Giffard, B., Beaumont, J., Clisant, S., & Wagner, L. French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3. Support Care Cancer 2012; 20: 3297–3305. doi: 10.1007/s00520-012-1439-2. Oliveira, A.F., Santos, I.M., Fernandes, S. et al. Validation study of the Functional Assessment of Cancer Therapy-Cognitive Function-Version 3 for the Portuguese population. BMC Psychol 10, 305 (2022). https://doi.org/10.1186/s40359-022-01018-w. Park, J., Bae, S., Jung, Y. S., & Jung. Y. M. The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer. Support Care Cancer 2015; 23(9): 2695-2703. doi: 10.1007/s00520-015-2632-x. Vardy, J., Wong, K., Yi. Q., Park, A., Maruff, P., Wagner, L., & Tannock, I. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14: 1111–1118. doi: 10.1007/s00520-006-0037-6. Wagner, L., Sweet, J., Butt, Z., Lai, J.-S., & Cella, D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy–cognitive function instrument. Journal of Supportive Oncology 2009; 7(6): W32-W39. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Fatigue Functional Assessment of Chronic Illness Therapy – Fatigue Scale LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-ES Functional Assessment of Cancer Therapy - Endocrine Symptoms LEARN MORE

FACT-M Functional Assessment of Cancer Therapy – Melanoma For patients with melanoma LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview A systematic review of the literature on quality of life in melanoma patients suggested an overwhelming need for a disease-specific subscale. The Functional Assessment of Cancer Therapy (FACT–Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify items of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients to be included in a pilot questionnaire. In stage III, the pilot measure and a semi-structured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank; after items were reviewed and evaluated. After final revisions were made, the FACT-M tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being. The face and content validity of the FACT–M was confirmed in melanoma patients and by professionals. MEASURE NAME: Functional Assessment of Cancer Therapy – Melanoma (FACT-M) VERSION: 4 NUMBER OF ITEMS: 51 PATIENT POPULATION: Melanoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Melanoma Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FACT-B DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-M can be obtained by registering for permission. Users are not permitted to translate the FACT-M without permission from FACIT.org. Permission from FACIT.org to translate the FACT-M may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Askew, R., Xing, Y., Plamer, J., Cella, D., Moye, L., & Cormier, J. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value in Health 2009; 12(8): 1144–1150. doi: 10.1111/j.1524-4733.2009.00570.x. Bharmal, M. Fofana, F., Barbosa, C., Williams, P., Mahnke, L., Marrel, A., & Schlichting, M. Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes 2017; 15:247. doi: 10.1186/s12955-017-0815-5. Bagge, AS.L., Ben-Shabat, I., Belgrano, V. et al. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. Ann Surg Oncol 23, 2062–2069 (2016). https://doi.org/10.1245/s10434-016-5103-9 Cormier, J., Davidson, L, Webster, K., Cella, D., Xing, Y., Ross, M., Gershenwald, J., Lee, J., Mansfield, P., Camacho, L., Kim, K., Papadopoulos, N., & Palmer, J. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma (FACT-Melanoma) questionnaire. Cancer 2008; 112(10): 2249-2257. doi: 10.1002/cncr.23424. Cormier, J., Davidson, L., Xing, Y., Webster, K., & Cella, D. Measuring quality of life in patients with melanoma: Development of the FACT-Melanoma subscale. Journal of Supportive Oncology 2005; 3(2): 139-145. Lindqvist Bagge AS, Wesslau H, Cizek R, Holmberg CJ, Moncrieff M, Katsarelias D, Carlander A, Olofsson Bagge R. Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. Eur J Surg Oncol. 2021 Sep 20:S0748-7983(21)00739-3. doi: 10.1016/j.ejso.2021.09.013. Epub ahead of print. PMID: 34600786. Robinson, D., Cormier, J., Zhao, N., Uhlar, C., Revicki, D., & Cella, D. Health-related quality of life among patients with metastatic melanoma: results from an international Phase 2 multicenter study. Melanoma Research 2012; 22(1):54–62. doi: 10.1097/CMR.0b013e32834d3da0. Swartz, R., Baum, G., Askew, R., Palmer, J., Ross, M., & Cormier, J. Reducing patient burden to the FACT-Melanoma quality-of-life questionnaire. Melanoma research 2012; 22(2): 158-63. doi: 10.1097/CMR.0b013e3283511dbf. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version LEARN MORE FACT-B Functional Assessment of Cancer Therapy – Breast LEARN MORE

View all available languages for this measure. BACK PROMIS Item Bank v1.0 Dyspnea Severity Languages English

PRRS Patient Roles and Responsibilities Scale For cancer patients LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Patient Roles and Responsibilities Scale (PRRS) was developed to enable a broader evaluation of the impact of cancer and cancer treatment, measuring ‘real world’ roles and responsibilities such as caring for others and financial and employment responsibilities. Version 2, modified in 2024, removes two items from the Jobs and Careers Subscale. MEASURE NAME: Patient Roles and Responsibilities Scale (PRRS) VERSION: 2 NUMBER OF ITEMS: 16 to 23 PATIENT POPULATION: Cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Responsibilities and Social Life, Family Well-being, Financial Well-Being, Jobs and Careers TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: CRRS , FACT-G Caregiver , FACT-G7 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PRRS can be obtained when licensing the measure. Users are not permitted to translate the PRRS without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the PRRS. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Shilling, V., Starkings, R., Jenkins, V. et al. Development and validation of the patient roles and responsibilities scale in cancer patients. Qual Life Res 27 , 2923–2934 (2018). https://doi.org/10.1007/s11136-018-1940-2. LICENSE THIS MEASURE Related Measures Related Measures CRRS Caregiver Roles and Responsibilities Scale LEARN MORE FACT-G Caregiver Functional Assessment of Cancer Therapy – General – Caregiver Version LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy - General - 7 Item Version LEARN MORE

Download this measure in English. BACK peds FACT-Br English Downloads Download PDF - (survivor) Child Download DOC - (survivor) Child Download PDF - Parent of Child Download DOC - Parent of Child Download PDF - (survivor) Adolescent Download DOC - (survivor) Adolescent Download PDF - Parent of Adolescent Download DOC - Parent of Adolescent

FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index For patients with Ascites LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-AI measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Ascites Index (FACIT-AI) VERSION: 4 NUMBER OF ITEMS: 13 PATIENT POPULATION: Cancer patients 18 years and older experiencing ascites RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Ascites Index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACIT-AD , FACIT-D , FAACT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-AI can be obtained by registering for permission. Users are not permitted to translate the FACIT-AI without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-AI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE FACIT-D Functional Assessment of Chronic Illness Therapy – Diarrhea LEARN MORE FAACT Functional Assessment of Anorexia/Cachexia Treatment LEARN MORE

Download this measure in English. BACK FACIT-F English Downloads Download PDF Download DOC

FACT-ICM-17 Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index For patients receiving immunotherapy treatment LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-ICM-17 is a brief, validated measure developed to assess the most common, distressing, and clinically useful symptomatic ICM-related immune-related adverse events. It is appropriate for use in research as well as routine symptom monitoring and management. MEASURE NAME: Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index VERSION: 1 NUMBER OF ITEMS: 17 PATIENT POPULATION: Cancer patients 18 years and older receiving immunotherapy treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: ICM TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible RELATED MEASURES: FACT-ICM , FACT- G, FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-ICM-17 can be obtained by registering for permission. Users are not permitted to translate the FACT-ICM-17 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-ICM-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Tometich DB, Hoogland AI, Li XY, Kirtane K, Small BJ, Barata A, Gonzalez BD, Chung CH, Shafique MR, Gray J, Khushalani NI, Postow MA, Cella D, Webster KA, Dicker AP, Jim HSL. Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to Facilitate Implementation in Research and Clinical Care. Available at SSRN: https://ssrn.com/abstract=5034323 or http://dx.doi.org/10.2139/ssrn.5034323 Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer. 2020 Apr 1;126(7):1550-1558. doi: 10.1002/cncr.32692. Epub 2020 Jan 8. PMID: 31914209. Webster KA, O’Connor ML, Hansen AR, Kircher S, Jim HSL, Dicker AP, Janda M, Ala-leppilampi K, Bingham CO III, Feliciano J, Henry NL, Steffen McLouth LE, Cella D. Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. J Cancer Metastasis Treat 2020;6:8. http://dx.doi.org/10.20517/2394-4722.2019.38. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-ICM Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

View all available languages for this measure. BACK PRRS Languages English Chinese - Simplified German

FACT-Cx Functional Assessment of Cancer Therapy – Cervix For patients with cancer of the Cervix LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Cx measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Cervix (FACT-Cx) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Cervical cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Cervical Cancer Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-CD , FACT-V , FACT-En DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Cx can be obtained by registering for permission. Users are not permitted to translate the FACT-Cx without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Cx may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Ashing-Giwa, K. Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study. Journal of Cancer Survivorship: Research and Practice 2008; 2(3):215-223. doi: 10.1007/s11764-008-0061-2. Chase, D., Huang, H., Wenzel, L., Cella, D., McQuellon, R., Long, H., Moore, D., & Monk, B. Quality of Life and survival in advanced cervical cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 2012; 125(2): 315-319. doi: 10.1016/j.ygyno.2012.01.047. Long, H., Bundy, B., Grendys, E., Benda, J., McMeekin, D., Sorosky, J., Miller, D., Eaton, L. & Fiorica, J. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2005; 23(21): 4626-4633. doi: 10.1200/JCO.2005.10.021. Monk, B., Sill, M., McMeekin, D., Cohn, D., Ramondetta, L., Boardman, C., Benda, J., & Cella, D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. Journal of Clinical Oncology 2009; 27(28): 4649-4655. doi: 10.1200/JCO.2009.21.8909. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-CD Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia LEARN MORE FACT-V Functional Assessment of Cancer Therapy – Vulva LEARN MORE FACT-En Functional Assessment of Cancer Therapy – Endometrial LEARN MORE

Download this measure in English. BACK FACT-ES English Downloads Download PDF Download DOC

View all available languages for this measure. BACK FACT-An Languages Afrikaans Albanian Arabic Bengali Bosnian Bulgarian Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Indonesian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Marathi Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu